Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of treatments for patients suffering from pain The company has a portfolio of proprietary clinical-stage product candidates targeting pain and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. The company also applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening technology (cHTS) to discover new product candidates for its portfolio or for its collaborators in the areas of pain, inflammation, oncology, and infectious disease. Ion Channel Programs N-type and T-type calcium channels and sodium channels in cells are major to the regulation of the body’s nervous and cardiovascular systems. The company is developing novel proprietary compounds to potentially treat pain and other diseases by selectively blocking ion channels in the neuronal cells responsible for pain signal transmission. Z160 and its N-type Calcium Channel Program The company’s advanced product candidate is Z160, a novel, oral N-type calcium channel blocker it is seeking to develop for the treatment of chronic pain. The company has completed Phase 1 clinical trials evaluating the pharmacokinetics and safety profiles of several new formulations of Z160, and the new formulations have demonstrated substantial bioavailability improvements. The Phase 2a trial in lumbosacral radiculopathy began in August 2012, and the Phase 2a trial in post-herpetic neuralgia began in December 2012. Z944 and its T-type Calcium Channel Program The company’s next advanced product candidate is Z944, a novel oral T-type calcium channel blocker it is seeking to develop for the treatment of pain indications. The company has completed Phase 1 single ascending dose and multiple ascending dose clinical studies of Z944 during 2012. It is planning to continue the clinical development of Z944 in 2013 with further studies to identify the optimal exposure of Z944 in humans and then potentially in an experimental proof-of-concept clinical trial in pain. Sodium Channel Biology In addition to the N-type and T-type calcium channels being targeted for pain, the company is pursuing another class of ion channel blockers for pain drug discovery and therapeutic intervention. Sodium channels, such as the Nav1.7 channel regulate pain signaling by mediating sodium ion currents that contribute to the excitability of both peripheral pain-sensing neurons and also neurons within the spinal cord that relay pain signals to the brain. Collaborations In February 2012, the company entered into a research collaboration agreement with Hydra Biosciences, to advance the development of its preclinical ion channel modulator product candidates for the treatment of pain. The company has a research collaboration and license agreement with Novartis, focused on the discovery of novel anti-cancer combinations. Through the collaboration, the company uses its proprietary cHTS platform to screen a library of molecules, including Novartis compounds, in multiple cell lines representing a spectrum of cancers to potentially discover novel single agent and combination therapies to treat various cancers. The company has a research collaboration agreement with Amgen Inc. or Amgen, focused on identifying synergistic combinations for two oncology targets of interest to Amgen. Patents and Other Proprietary Rights As of February 28, 2013, the company’s patent estate, on a worldwide basis, included 136 issued patents and 118 pending patent applications, with claims covering all of its current clinical stage product candidates and select preclinical and research programs. Of the issued patents, 36 are issued in the United States. Of the pending patent applications, 23 are United States non-provisional or provisional applications. The company is building a portfolio which includes 29 patent families, including 63 issued patents and 29 pending patent applications worldwide, which cover various new chemical entities and their methods of use, as well as formulations of these molecules. History The company was founded in 2000. It was incorporated in Delaware in 2000. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. in 2010.
zalicus inc (ZLCS:NASDAQ CM)
245 First Street
Cambridge, MA 02142
|No competitor information is available for ZLCS.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ZALICUS INC, please visit www.zalicus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.